

PEB CONCLUDES COMMERCIAL AGREEMENT WITH FACEY MEDICAL GROUP IN US

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) has concluded a commercial agreement with Facey Medical Group, a physician owned medical group in California. The agreement covers the use of Cxbladder Detect and Cxbladder Monitor for Facey Medical Group patients.

Facey Medical Group is a multi-specialty medical group with over 180 physicians providing care to more than 170,000 patients in the North & East regions of Los Angeles & Ventura Counties in California. This makes it similar in size to the Mid-Central District Health Board in New Zealand. Facey Medical Group is also one of six California physician groups affiliated with, or owned by Providence Health & Services, one of the largest health systems in the Western United States.

CEO of Pacific Edge, David Darling, said: “Physician owned organisations such as the Facey Medical Group are an important customer group for Pacific Edge as we continue to expand the adoption and commercial use of Cxbladder in the US. We were approached by the Group following a number of the urologists utilising our products and we are pleased to move into a formal commercial relationship with them. Whilst test volumes are not expected to be large compared to healthcare organisations such as Kaiser Permanente, this agreement demonstrates the ongoing commercial adoption of Cxbladder in the US as we continue to position Cxbladder as the preferred diagnostic test for urologists evaluating patients for bladder cancer.”

ENDS

For more information contact:

David Darling, Chief Executive Officer, Pacific Edge Ltd, T: +64 (3) 479 5800

For media assistance, please contact Jackie Ellis on T: +64 27 246 2505 or email jackie@ellisandco.co.nz

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com

Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com

Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com

Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com

Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com

Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.